ELVN ENLIVEN THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, ENLIVEN THERAPEUTICS INC reported revenue of n/a, net income of −$32.5M and diluted EPS of −$0.49; for the fiscal year ended December 2025 revenue was n/a.
ELVN annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$120M, net income −$104M (margin n/a), EPS −$1.83
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$105M, net income −$89.0M (margin n/a), EPS −$1.89
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$83.5M, net income −$71.6M (margin n/a), EPS −$2.01
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$38.8M, net income −$37.7M (margin n/a), EPS −$12.05
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$24.8M, net income −$24.7M (margin n/a), EPS −$10.73
ELVN quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$32.5M, EPS −$0.49
- Quarter ended Mar 31, 2026: revenue n/a, net income −$23.6M, EPS −$0.38
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$29.7M, EPS −$0.45
- Quarter ended Sep 30, 2025: revenue n/a, net income −$20.1M, EPS −$0.32
- Quarter ended Jun 30, 2025: revenue n/a, net income −$25.3M, EPS −$0.49
- Quarter ended Mar 31, 2025: revenue n/a, net income −$28.5M, EPS −$0.57
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$23.2M, EPS −$0.46
- Quarter ended Sep 30, 2024: revenue n/a, net income −$23.2M, EPS −$0.48
- Quarter ended Jun 30, 2024: revenue n/a, net income −$20.0M, EPS −$0.41
- Quarter ended Mar 31, 2024: revenue n/a, net income −$22.7M, EPS −$0.54
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$19.4M, EPS −$0.29
- Quarter ended Sep 30, 2023: revenue n/a, net income −$20.8M, EPS −$0.51
- Quarter ended Jun 30, 2023: revenue n/a, net income −$16.7M, EPS −$0.41
- Quarter ended Mar 31, 2023: revenue n/a, net income −$14.7M, EPS −$0.80
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$9.55M, EPS −$2.91
- Quarter ended Sep 30, 2022: revenue n/a, net income −$10.6M, EPS −$3.27
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.89M, EPS −$2.86
- Quarter ended Mar 31, 2022: revenue n/a, net income −$8.67M, EPS −$3.01
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income $12.3M, EPS −$8.67
- Quarter ended Sep 30, 2021: revenue n/a, net income −$13.6M, EPS −$0.74
ELVN cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$70.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$73.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$61.3M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$32.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$19.1M, share buybacks n/a
ELVN balance sheet
- Jun 30, 2026: cash $136M, total assets $910M, total liabilities $15.1M, shareholders' equity $895M
- Mar 31, 2026: cash $132M, total assets $465M, total liabilities $11.5M, shareholders' equity $453M
- Dec 31, 2025: cash $98.9M, total assets $476M, total liabilities $16.6M, shareholders' equity $460M
- Sep 30, 2025: cash $102M, total assets $491M, total liabilities $14.8M, shareholders' equity $476M
- Jun 30, 2025: cash $119M, total assets $504M, total liabilities $15.4M, shareholders' equity $488M
- Mar 31, 2025: cash $102M, total assets $303M, total liabilities $14.3M, shareholders' equity $288M
- Dec 31, 2024: cash $124M, total assets $326M, total liabilities $15.9M, shareholders' equity $310M
- Sep 30, 2024: cash $101M, total assets $305M, total liabilities $17.0M, shareholders' equity $288M
Is ELVN profitable?
No. ENLIVEN THERAPEUTICS INC lost $106M over the last four quarters.
What is ELVN's EPS?
Diluted earnings per share over the last four quarters were −$1.64; −$0.49 in the latest quarter.